Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8922917 | Personalized Medicine in Psychiatry | 2018 | 7 Pages |
Abstract
The defined Cognitive Gene Risk Profile has potential utility in participant selection/stratification for preclinical AD trials that incorporate Aβ-amyloid and where decline in cognition is essential to determine therapeutic effectiveness.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Tenielle Porter, Victor L. Villemagne, Greg Savage, Lidija Milicic, Yen Ying Lim, Paul Maruff, Colin L. Masters, David Ames, Ashley I. Bush, Ralph N. Martins, Stephanie Rainey-Smith, Christopher C. Rowe, Kevin Taddei, David Groth, Giuseppe Verdile,